SCHEDULE: BridgeBio Oncology Completes Merger, Key Investors Boost Stake

BridgeBio Oncology Therapeutics, formerly Helix Acquisition Corp. II, completed its business combination with TheRas, Inc., leading to significant shareholding changes for key investors including Bihua Chen.

Summary

• The business combination between Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics, Inc.) and TheRas, Inc. (Legacy BBOT) was completed on August 11, 2025.
• Helix underwent domestication as a Delaware corporation on August 11, 2025.
• Reporting Persons (Helix Holdings II LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, and Bihua Chen) participated in PIPE Investments, purchasing 6,998,031 shares of Common Stock at $10.7173 per share on August 11, 2025.
• The Sponsor forfeited a total of 460,814 shares (307,874 Sponsor Forfeited Shares during domestication and 152,940 shares of Common Stock prior to the merger).
• All Helix Class A ordinary shares and Legacy BBOT capital stock converted into Common Stock of the Issuer.
• Shares beneficially owned by Reporting Persons (excluding PIPE shares) are subject to a one-year lock-up period from the later of the Form 10 Information filing and the Closing Date.
• A Registration Rights Agreement was entered into, obligating the Issuer to register for resale certain shares held by Reporting Persons.
• As of August 11, 2025, Bihua Chen beneficially owned 17,878,594 shares of Common Stock, representing 22.6% of the outstanding shares.

Sentiment

Score: 7

Explanation: The completion of the business combination and significant PIPE investment by key shareholders indicates a positive step for the company. The substantial beneficial ownership by Bihua Chen, who is also a director, suggests strong alignment of interests. The lock-up period, while a restriction, also signals long-term commitment from these investors.

Positives

• Completion of the business combination, successfully transitioning Helix Acquisition Corp. II into BridgeBio Oncology Therapeutics, Inc.
• Significant investment by Reporting Persons through PIPE, indicating confidence in the company at a price of $10.7173 per share.
• Bihua Chen's continued role as a director and substantial beneficial ownership (22.6%) aligns her interests with those of other shareholders.
• The lock-up agreement on a significant portion of shares held by key investors signals a long-term commitment to the company's success.

Negatives

• The Sponsor forfeited a total of 460,814 shares in connection with the domestication and merger transactions.
• The lock-up agreement restricts the transferability of a significant portion of shares for one year, potentially limiting immediate liquidity for Reporting Persons.

Risks

• Transfer restrictions on a significant portion of shares held by Reporting Persons for one year could impact market liquidity for those shares.
• Future actions by Reporting Persons, including potential sales or acquisitions of additional securities, could influence the Issuer's stock price.
• The Reporting Persons may seek to influence management or the Board, which could lead to strategic shifts.

Future Outlook

Reporting Persons acquired shares for investment purposes and intend to continue reviewing their investments. They may acquire additional securities or dispose of existing holdings in the future, potentially through open market or private transactions, block sales, or in connection with extraordinary corporate transactions. They expect to actively evaluate such transactions and may seek to influence management or the Board to maximize stockholder value.

Management Comments

• Ms. Chen, as a director of the Issuer, may communicate with management, other Board members, and stockholders regarding operational, strategic, financial, or governance matters to maximize stockholder value.

Industry Context

This filing marks the completion of a SPAC business combination, a common strategy for private companies like TheRas, Inc. (Legacy BBOT) to go public. The involvement of specialized healthcare investment funds like Cormorant Asset Management highlights continued investor interest in the oncology therapeutics sector, a high-growth area within biotechnology.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: The completion of the business combination and the significant investment by key shareholders may instill confidence. The lock-up agreement provides stability by restricting immediate sales from major investors.
• Management: The continued involvement of Bihua Chen as a director and her stated intent to potentially influence management and the Board indicates active oversight from a major shareholder.

Next Steps

• Filing of Form 10 Information with the SEC (relevant for lock-up period calculation).
• Potential future acquisitions or dispositions of securities by Reporting Persons.
• Ongoing evaluation of investments in the Issuer by Reporting Persons.
• Possible influence on management or the Board by Reporting Persons.

Key Dates

Recommendation

The filing details the completion of a SPAC business combination and related share transactions, including a significant PIPE investment. While the completion of the merger is a positive step, the filing primarily focuses on ownership structure rather than operational or financial performance. The lock-up agreement on a substantial portion of shares held by key investors suggests a long-term commitment, but also limits immediate liquidity. Without further operational or financial details from BridgeBio Oncology Therapeutics, a 'hold' recommendation is appropriate as the market digests the new corporate structure and investor base.

Keywords

BridgeBio Oncology Therapeutics, Helix Acquisition Corp. II, TheRas Inc, Business Combination, Merger, SEC Filing, Schedule 13D, Shareholding, PIPE Investment, Bihua Chen, Cormorant Asset Management, Biotechnology, Oncology, Corporate Governance, Lock-Up Agreement, Registration Rights